Therapeutic Response

PD-L1 >= 1%, Wild type ALK, and Wild type EGFR status confers therapeutic sensitivity to Pembrolizumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Keytruda (pembrolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pembrolizumab for the first-line treatment of patients with non-small cell lung cancer expressing PD-L1 [Tumor Proportion Score (TPS) >=1%], as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.